Cerebrolysin 60mg

Contents

Use this guide as a structured review page. The same headings appear for every protocol so clients and the care team can scan the page consistently.

Quickstart Highlights

Cerebrolysin is a porcine brain‑derived peptide preparation containing low‑molecular‑weight neuropeptides and free amino acids that crosses the blood–brain barrier to support neuronal survival[1]. It mimics endogenous neurotrophic factors (e.g., NGF, BDNF) and modulates neuroinflammatory mediators[1][2]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

• Reconstitute: Add 3.0 mL bacteriostatic water → 20 mg/mL concentration.
• Typical daily range: 20–32 mg once daily (gradual titration); split doses for >20 mg.
• Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 200 mcg (0.2 mg) on a U‑100 insulin syringe.
• Storage: Lyophilized at room temperature ≤25 °C (≤77 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days; do not freeze.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

• Frequency: Inject once or twice daily subcutaneously as shown above. Doses exceeding 100 units (1.0 mL) should be split into AM and PM administrations. Clinical literature describes daily doses ranging from 215 mg (1 mL of commercial solution) up to higher IV infusions[1]; this protocol uses a conservative subcutaneous approach with gradual titration.

Reconstitution Steps

Reference-derived details for Cerebrolysin 60mg.

• Draw 3.0 mL bacteriostatic water with a sterile syringe.
• Inject slowly down the vial wall; avoid foaming.
• Gently swirl/roll until dissolved (do not shake).
• Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 7 days[8]. Open source

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration. At maintenance dose (~32 mg/day), each 60 mg vial provides approximately 1.9 doses.

• Peptide Vials (Cerebrolysin, 60 mg each):
• Peptide Vials (Cerebrolysin, 60 mg each):: 8 weeks ≈ 26 vials
• Peptide Vials (Cerebrolysin, 60 mg each):: 12 weeks ≈ 42 vials
• Peptide Vials (Cerebrolysin, 60 mg each):: 16 weeks ≈ 58 vials
• Insulin Syringes (U‑100): Count based on injections per day (1–2 depending on dose).
• Insulin Syringes (U‑100): Count based on injections per day (1–2 depending on dose).: Week 1 (1/day): 7 syringes
• Insulin Syringes (U‑100): Count based on injections per day (1–2 depending on dose).: Weeks 2–8 (2/day): 98 syringes
• Insulin Syringes (U‑100): Count based on injections per day (1–2 depending on dose).: 8 weeks total: 105 syringes
• Insulin Syringes (U‑100): Count based on injections per day (1–2 depending on dose).: 12 weeks total: 161 syringes
• Insulin Syringes (U‑100): Count based on injections per day (1–2 depending on dose).: 16 weeks total: 217 syringes
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.: 8 weeks (26 vials): 78 mL → 8 × 10 mL bottles
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.: 12 weeks (42 vials): 126 mL → 13 × 10 mL bottles
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.: 16 weeks (58 vials): 174 mL → 18 × 10 mL bottles
• Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
• Alcohol Swabs: One for the vial stopper + one for the injection site each administration.: 8 weeks (105 injections): 210 swabs → recommend 3 × 100‑count boxes
• Alcohol Swabs: One for the vial stopper + one for the injection site each administration.: 12 weeks (161 injections): 322 swabs → recommend 4 × 100‑count boxes
• Alcohol Swabs: One for the vial stopper + one for the injection site each administration.: 16 weeks (217 injections): 434 swabs → recommend 5 × 100‑count boxes

Protocol Overview

Concise summary of the daily regimen.

• Goal: Support neuroprotection and neuronal survival through neurotrophic factor mimicry[1][2]. Open source
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 20–32 mg daily with gradual titration.
• Reconstitution: 3.0 mL per 60 mg vial (20 mg/mL) for accurate unit measurements.
• Storage: Lyophilized at room temperature (≤25 °C); reconstituted refrigerated (2–8 °C); do not freeze.

Dosing Protocol

Suggested daily titration approach.

• Start: 20 mg daily (100 units); increase by ~4 mg (20 units) per week as tolerated.
• Target: 28–32 mg daily by Weeks 3–4.
• Frequency: Once or twice per day (subcutaneous); split doses >20 mg into AM/PM.
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.
• Timing: Any consistent time(s); rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at controlled room temperature ≤25 °C (≤77 °F) in dry, dark conditions; do not freeze[8]. Open source
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days; protect from light[8]. Open source
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose, timing (AM/PM), and site rotation to maintain consistency.
• For doses exceeding 100 units (1.0 mL), split into two separate injections at different sites.

How This Works

Cerebrolysin is a multicomponent peptide preparation derived from porcine brain tissue, containing biologically active neuropeptides and amino acids with molecular weights below 10 kDa[1]. This low molecular weight allows it to cross the blood–brain barrier and exert neurotrophic effects similar to endogenous factors like nerve growth factor (NGF) and brain‑derived neurotrophic factor (BDNF)[1][2]. Preclinical studies demonstrate neuroprotective effects including reduced infarct size and improved recovery in ischemia models[4][5]. Human trials have examined its use in stroke, dementia, and traumatic brain injury with mixed but generally favorable tolerability profiles[2][3].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

• Preclinical models consistently show neuroprotective effects including reduced neuronal damage and improved functional recovery after ischemic insult[4][5]. Open source
• Meta‑analyses of human dementia trials suggest modest cognitive benefits with daily IV infusions[2]; stroke trial results have been more variable[3]. Open source
• Generally well tolerated in short‑term use[2]; occasional mild injection‑site reactions (redness, discomfort) may occur with subcutaneous administration. Open source
• Rare reports of dizziness, headache, or gastrointestinal upset; discontinue and consult a professional if significant adverse effects occur.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain a nutrient‑dense diet rich in omega‑3 fatty acids, antioxidants, and B‑vitamins to support neuronal health.
• Engage in regular aerobic exercise and cognitive stimulation to reinforce neuroplasticity.
• Prioritize quality sleep (7–9 hours) and stress management to optimize recovery and brain function.
• Avoid excessive alcohol and other neurotoxic substances during the protocol.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources[6][7].

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a 2–4 cm skinfold; insert the needle at 45–90° into subcutaneous tissue[6]. Open source
• Do not aspirate for subcutaneous injections; inject slowly and steadily[7]. Open source
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[9]. Open source
• For split‑dose protocols (AM/PM), use different injection sites for each administration.

Recommended Source

We recommend Prime Lab Peptides for high‑purity Cerebrolysin (60 mg).

• High‑purity, third‑party‑tested lots with batch COAs.
• Consistent, ISO‑aligned handling and documentation.
• Reliable fulfillment to maintain product integrity.

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

• Do not start, stop, combine, or change a protocol based only on website content.
• Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References

— Cerebrolysin Monograph: mechanism, pharmacology, and clinical applications (2018)

• Cerebrolysin (60mg Vial) Open source
• International Peptide Society — Cerebrolysin Monograph: mechanism, pharmacology, and clinical applications (2018) View Source Open source
• Alzheimer’s Drug Discovery Foundation — Cerebrolysin cognitive vitality report: evidence synthesis and safety overview (2016) View Source Open source
• Zhang et al., Med Sci Monit (PMC) — Meta‑analysis of Cerebrolysin efficacy and safety in acute ischemic stroke (2017) View Source Open source
• Kurkin et al., PLOS One — Neuroprotective action of Cerebrolysin in acute/chronic brain ischemia in rats (2021) View Source Open source
• Espinoza et al., Behav Brain Res (PubMed) — Cerebrolysin neuroprotection and neurorepair in diabetic rat model (2024) View Source Open source
• CDC — Injection safety: preventing unsafe injection practices in clinical settings (2024) View Source Open source
• WHO — Injection safety: best practices for healthcare providers guide (2016) View Source Open source
• Ever Neuro Pharma — Cerebrolysin dosage recommendation and storage specifications (SPC 2016) View Source Open source
• NCBI Bookshelf — Subcutaneous injection technique: preparation, administration, and site rotation View Source Open source
• Subcutaneous Drug Delivery Review (PMC) — Pharmacologic considerations and best practices for subcutaneous administration View Source Open source
• Cognitive Frailty & Cerebrolysin Review (PMC) — Evidence for peptidergic nootropics in age‑related cognitive decline View Source Open source
• Neurotrophic Factors & Neurodegeneration (PMC) — Role of NGF/BDNF pathways in neuroprotection and neuroplasticity View Source Open source
• Prime Lab Peptides — Cerebrolysin (60 mg) product page (quality documentation and batch COAs) View Source